Peginterferon alfa-2b
- Generic Name
- Peginterferon alfa-2b
- Brand Names
- Pegintron, Sylatron
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 215647-85-1
- Unique Ingredient Identifier
- G8RGG88B68
- Background
Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2b is indicated for the treatment of HCV in combination with Ribavirin and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Melanoma
- Associated Therapies
- -
A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)
- Conditions
- Interventions
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 660
- Registration Number
- NCT01280656
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients
- Conditions
- Interventions
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 51
- Registration Number
- NCT01016912
- Locations
- 🇯🇵
Local Institution, Minato-Ku, Tokyo, Japan
Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2009-06-12
- Last Posted Date
- 2019-10-09
- Target Recruit Count
- 116
- Registration Number
- NCT00919633
- Locations
- 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-10-28
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 32
- Registration Number
- NCT00781274
- Locations
- 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-10-28
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 109
- Registration Number
- NCT00780910
- Locations
- 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 189
- Registration Number
- NCT00780416
- Locations
- 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan
Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)
- Conditions
- Interventions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1077
- Registration Number
- NCT00724295
Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 496
- Registration Number
- NCT00709228
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
- Conditions
- Interventions
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT00539591
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
🇺🇸The Children's Cancer Hospital at UT M.D. Anderson Cancer Center, Houston, Texas, United States
Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C
- Conditions
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2007-01-04
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 40
- Registration Number
- NCT00418054
- Locations
- 🇪🇬
Department of Tropical Medicine & Infectious Diseases, Alexandria University, Alexandria, Egypt
🇪🇬Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine, Tanta, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.